Skip to main content
Log in

Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture

  • Clinical Trials Report
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Black DM, Delams PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809–1822.

    Article  PubMed  CAS  Google Scholar 

  2. Colón-Emeric C, Messenbrink P, Lyles K, et al.: Potential mediators in the reduction of mortality with zoledronic acid after hip fracture [abstract 1030]. Presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research. Montreal, Quebec, Canada; September 12–16, 2008.

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silverman, S.L. Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture. Curr Osteoporos Rep 7, 1–2 (2009). https://doi.org/10.1007/s11914-009-0001-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-009-0001-8

Keywords

Navigation